• Barclays sets a price target of $136 for Zoetis Inc. (NYSE:ZTS), indicating a potential increase of approximately 15.1%.
• Zoetis showcases its strategies and innovations at the Piper Sandler 37th Annual Healthcare Conference, emphasizing its leadership in the animal health industry.
• The company's stock has experienced significant fluctuations, with a high of $181.85 and a low of $115.25 over the past year, maintaining a strong market capitalization of approximately $52.07 billion.

Zoetis Inc. (NYSE:ZTS) is a prominent player in the animal health industry, providing a range of products and services for livestock and pets. The company is known for its innovative solutions and strong market presence. Zoetis competes with other major companies in the healthcare sector, focusing on animal health, which is a growing market.

On December 8, 2025, Barclays set a price target of $136 for Zoetis, suggesting a potential price increase of approximately 15.1% from its current trading price of $118.16. This optimistic outlook reflects confidence in Zoetis's market strategies and growth potential. The stock's recent performance shows a slight decrease of 0.41%, with a trading range between $117.52 and $120.15 for the day.

Zoetis recently presented at the Piper Sandler 37th Annual Healthcare Conference, a key event for companies in the healthcare sector. This platform allowed Zoetis to discuss its strategies, innovations, and future outlooks, reinforcing its position as a leader in the animal health industry. Engaging with investors and stakeholders at such events is crucial for maintaining market confidence.

The stock has experienced significant fluctuations over the past year, with a high of $181.85 and a low of $115.25. Despite these variations, Zoetis maintains a strong market capitalization of approximately $52.07 billion. The trading volume for the day stands at 4,361,906 shares, indicating active investor interest in the stock.

Zoetis's participation in industry conferences and its strategic initiatives are vital for its continued growth and market performance. As the company navigates the dynamic healthcare landscape, its ability to innovate and engage with stakeholders will be key to achieving the price target set by Barclays.